## Clinical Diagnosis This patient has **systolic heart failure with reduced ejection fraction (HFrEF)** secondary to hypertensive cardiomyopathy. The combination of hypertension, LVH with strain, reduced EF (35%), and classic HF symptoms (orthopnea, PND, dyspnea on exertion) confirms the diagnosis. ## Pathophysiology **Key Point:** Chronic hypertension causes concentric LVH → diastolic dysfunction → eventual systolic dysfunction and chamber dilation. The patient's EF of 35% places him in **NYHA Class III** (symptomatic at rest or minimal exertion), making this **Stage C HFrEF** (structural disease with prior or current symptoms). ## Management Algorithm ```mermaid flowchart TD A[HFrEF diagnosed]:::outcome --> B{Acute decompensation?}:::decision B -->|Yes| C[Diuretics, vasodilators, inotropes]:::action B -->|No| D[Stable chronic HF]:::outcome D --> E[Start GDMT]:::action E --> F[ACE-I/ARB + Beta-blocker + MRA]:::action F --> G{Ischemic etiology?}:::decision G -->|Suspected| H[Coronary angiography]:::action G -->|Unlikely| I[Optimize GDMT, follow-up echo]:::action H --> J[Revascularize if indicated]:::action ``` ## Guideline-Based Management (ACC/AHA 2022, ESC 2021) ### First-Line Agents (GDMT) | Drug Class | Mechanism | Indication | Timing | |---|---|---|---| | **ACE-I / ARB** | Vasodilation, neurohormonal antagonism | All HFrEF | Start early | | **Beta-blocker** | Reduce sympathetic drive, improve remodeling | All HFrEF | Start early, uptitrate | | **MRA** (spironolactone/eplerenone) | Aldosterone antagonism | All HFrEF with EF ≤35% | Add after ACE-I + BB | | **SGLT2 inhibitor** | Improve cardiac metabolism, reduce afterload | All HFrEF (new evidence) | Add early | **High-Yield:** The patient is **NOT in acute decompensation** (no hypotension, no cardiogenic shock), so inotropes are NOT indicated. ### Why Coronary Angiography? **Clinical Pearl:** Although this patient has a clear hypertensive etiology, **ischemic cardiomyopathy** (CAD causing HFrEF) is the most common cause of HFrEF in India. Given his age (58), diabetes, and hypertension, he has significant coronary risk. Angiography is recommended to **rule out obstructive CAD** that may require revascularization [cite:Harrison 21e Ch 235]. **Key Point:** Coronary angiography is indicated in all patients with HFrEF and: - Anginal symptoms - Diabetes - Multiple risk factors for CAD - Ischemic ECG changes (even if not acute) ## Why This Option Is Correct The correct approach combines: 1. **Immediate GDMT initiation** (furosemide for congestion, lisinopril for afterload reduction and remodeling, carvedilol for beta-blockade) 2. **Coronary risk stratification** (angiography to exclude CAD) 3. **Staged optimization** (add MRA and SGLT2i after stabilization) ## Monitoring - Repeat echocardiography in 3 months to assess response - Uptitrate ACE-I and beta-blocker to target doses - Monitor renal function and potassium (especially with MRA)
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.